Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Young Healthy Humans Demonstrate Reduced Executive Function in Moderate Hypoxia
Buchholtz, Zachary A. , Baker, Sarah , Trenerry, Max R., Clifton, Haider R., Holmes, David R. , Wiggins, Chad C. , Joyner, Michael J. , Curry, Timothy B. , Uchida, Koji

Mayo Clinic

The FASEB Journal | April 16, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.01943 Get It

Background Cognitive deficits resulting from mild hypoxia are difficult to quantify and reproduce consistently. The changes in executive function during acute hypoxia are still controversial. The purpose of present study was to assess changes in executive function during acute moderate hypoxia using a continuous performance test (Connors’ Continuous Performance test, CCPT‐II). Methods Nine young, healthy adults (7 women; 28 ± 1 years; BMI: 24.5 ± 3.0 kg·m −2 ) performed two sets of CCPT‐II during two different conditions: 1) 7 minutes of baseline (fraction of inspired oxygen (F i O 2 ) = 0.21) and 2) 10 minutes of hypoxia (F i O 2 =0.118). The CCPT‐II is a test of executive cognitive function which requires subjects to strike a key when any letter except the letter X appeared on a computer monitor as quickly and accurately as possible. Reaction time, commission errors (response to X), and omission errors (failure to respond to a letter other than X) were recorded for each 140s of the CCPT‐II block. Arterial oxygen concentration (P a O 2 ) was measured during the last 30sec of baseline and hypoxia from brachial artery catheter samples. Results P a O 2 was reduced in hypoxia ( baseline : 103.1 ± 1.5 mmHg vs. hypoxia : 43.2 ± 1.0 mmHg, P <0.01). During the trials of the CCPT‐II performed during hypoxia, reaction time was lower (i.e. faster) than during baseline ( baseline : 451 ± 18 ms. vs. hypoxia : 437 ± 13 ms., P<0.01). Additionally, the number of commission errors was greater in hypoxia ( baseline : 1.3 ± 0.6 errors·block −1 vs. hypoxia : 2.1 ± 0.8 errors·block −1 , P<0.01). However, the number of omission errors was not different between the two conditions ( baseline : 0.4 ± 0.2 errors·block −1 vs. hypoxia : 0.2 ± 0.1 errors·block −1 , P=0.92). Conclusions The number of commission errors increased and the reaction time decreased during the CCPT‐II test performed in moderate hypoxia compared to baseline, demonstrating a decline in cognitive function during hypoxia. The faster and less accurate responses during hypoxia suggest a suppression of inhibitory pathways in the prefrontal or motor cortex that may contribute to the observed acute reduction in executive cognitive function. Support or Funding Information This project was funded by the Office of Naval Research (ONR), grant number N00014‐18‐D‐7001‐TO1.
Skeletal muscle blood flow and vascular conductance are enhanced in humans with high‐affinity hemoglobin during handgrip exercise in severe hypoxia
Dominelli, Paolo B. , Shepherd, John R. A. , Wiggins, Chad C. , Senefeld, Jonathon W. , Baker, Sarah E. , Uchida, Kôji , Joyner, Michael J.

Mayo Clinic

The FASEB Journal | April 15, 2020 | Volume: 34 | Issue: S1 | Pages: 1-1

10.1096/fasebj.2020.34.s1.00495 Get It

Background In humans, exercise tolerance is determined by the balance of diffusive and convective elements of oxygen transport. Mathematical models have suggested that alterations in hemoglobin‐oxygen (Hb‐O 2 ) binding affinity (P 50 ) have minimal effects of on oxygen delivery. However, there is limited experimental data in humans to evaluate these models during exercise in humans. Purpose We sought to investigate skeletal muscle blood flow and vascular conductance (hyperemic response to exercise and hypoxia) during exercise in otherwise healthy participants with chronically high Hb‐O 2 affinity (HAH). We hypothesized that patients with HAH would have a blunted hyperemic response to both handgrip and hypoxia due to the marked polycythemia that is typical in participants with HAH compared to controls. Methods Participants with HAH (n=6, 3 men, age= 37±12 yr, P 50 =15±2 mmHg) and control participants matched for age, sex, and BMI (CTL, n=5, 3 men, age=41±8 yr, and P 50 =26±1 mmHg) completed two intensities (10% and 20% maximal voluntary contraction (MVC)) of rhythmic handgrip exercise with a duty cycle of 1s contraction and 2s relaxation (20 contractions·min −1 ). Each exercise intensity was performed breathing three different gas mixtures: 21%, 15%, and 10% oxygen. Brachial artery mean blood velocity was measured using Doppler ultrasound. Beat‐by‐beat blood pressure was measured via arterial catheterization. Forearm blood flow (FBF) was calculated as the product of mean blood velocity (cm·s −1 ) and brachial artery cross‐sectional area (cm 2 ) and expressed as milliliters per minute (mL·min −1 ), and forearm vascular conductance (FVC) was calculated as (FBF) × (mean arterial pressure) −1 × 100 and expressed as mL·min −1 ·mmHg −1 . Data were analyzed using a three‐way ANOVA (Inspirate [21%, 15%, 10% O 2 ], group [CTL, HAH], handgrip intensity [Rest, 10% and 20% MVC]). Results During normoxia (21% O 2 ), groups were not different in FBF (P>0.05), FVC (P>0.05) or arterial saturation (S a O 2 , P=0.54). Similarly, the moderate hypoxia condition (15% O 2 ), groups were not different in FBF (P>0.05), or FVC (P>0.05) despite a preservation in arterial saturation in HAH (S a O 2 , CTL: 89.0±0.7% vs. HAH: 95.1±1.7%, P<0.001). However, with more severe hypoxic exposure (10% O 2 ), FBF and FVC were higher in HAH than controls during the 20% MVC exercise (P<0.05). HAH also had higher FBF (P<0.05) and trended towards higher FVC in the 10% MVC exercise (P=0.08). Interestingly, arterial saturation was drastically higher for HAH at the end of handgrip exercise (20% MVC) in 10% O 2 (CTL: 69.2±4.5% vs. HAH: 89.1±1.4%, P<0.001). Conclusion As predicted in mathematical models, Hb‐O 2 binding affinity had little effect on skeletal muscle blood flow and forearm vascular conductance during light exercise under normoxic and moderate hypoxic conditions (21% and 15% O 2 ). However, with a greater physiological stress to skeletal muscle O 2 uptake in a more severe hypoxic condition (10% O 2 ), participants with HAH, contrary to our initial hypothesis, had preserved arterial O 2 saturation and a greater hyperemic response than controls. Support or Funding Information This work was supported by the NIH (5T32DK007352‐39 to CCW, R35HL139854 to MJJ) Rest 10% MVC 20% MVC FBF, mL·min − 1 21% O 2 CTL 87 ± 8 327 ± 25 589 ± 26 HAH 142 ± 19 420 ± 29 716 ± 68 15% O 2 CTL 173 ± 61 357 ± 63 707 ± 62 HAH 156 ± 66 539 ± 111 930 ± 143 10% O 2 CTL 154 ± 72 386 ± 81 668 ± 57 HAH 244 ± 133 703 ± 199 * 932 ± 118 * FVC, mL·min − 1 ·mmHg − 1 21% O 2 CTL 94 ± 9 356 ± 27 621 ± 24 HAH 130 ± 19 363 ± 25 617 ± 63 15% O 2 CTL 187 ± 63 384 ± 54 758 ± 53 HAH 137 ± 44 453 ± 79 764 ± 226 10% O 2 CTL 171 ± 71 431 ± 73 708 ± 67 HAH 221 ± 109 718 ± 136 917 ± 172 Abbreviations: FBF, forearm blood flow; FVC, forearm vascular conductance; MVC, maximal voluntary contraction; CTL, control group; HAH, high‐affinity Hb group. Values are presented as mean±SE. * indicates significant difference (P<0.05) from CTL group at same %MVC.
The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites
Mato, Anthony R. , Nabhan, Chadi , Lamanna, Nicole , Kay, Neil E. , Grinblatt, David L. , Flowers, Christopher R. , Swern, Arlene S., Sullivan, Kristen , Flick, E. Dawn, Ussery, Sarah M. Gressett, Gharibo, Mecide, Kiselev, Pavel , Sharman, Jeff P. , Kay, Neil E , Farber, Charles Michael , Davids, Matthew S.

Mayo Clinic

Blood Advances | April 9, 2020 | Volume: 4 | Issue: 7 | Pages: 1407-1418

10.1182/bloodadvances.2019001145 | PMID 32271900 Get It

Abstract Optimal treatment of chronic lymphocytic leukemia (CLL) remains unclear. The Connect CLL Registry, a United States–based multicenter prospective observational cohort study, enrolled 1494 patients between 2010 and 2014 from predominantly community-based settings. Patients were grouped by line of therapy (LOT) at enrollment. With a median follow-up of 46.6 months (range, 0-63.0 months), median overall survival (OS) was not reached in LOT1, 63.0 months (95% confidence interval [CI], 46.0-63.0 months) in LOT2, and 38.0 months (95% CI, 33.0-47.0 months) in LOT≥3. Bendamustine and rituximab (BR; 33.5%); fludarabine, cyclophosphamide, and rituximab (FCR; 21.4%); and rituximab monotherapy (18.5%) were the most common regimens across LOTs. Median event-free survival (EFS) was similar in patients treated with BR (59.0 months) and FCR (55.0 months) in LOT1; median OS was not reached. In multivariable analysis, BR or FCR vs other treatments in LOT1 was associated with improved EFS (hazard ratio [HR], 0.60; P &lt; .0001) and OS (0.67; P = .0162). Using the Kaplan-Meier product limit, ibrutinib vs other treatments improved OS in LOT2 (HR, 0.279; P = .009), LOT3 (0.441; P = .011), and LOT≥4 (0.578; P = .043). Prognostic modeling of death at 2 years postenrollment identified 3 risk groups: low (mortality rate, 6.2%), medium (14.5%), and high (27.4%). The most frequent adverse events across LOTs were pneumonia (11.6%) and febrile neutropenia (6.2%). These data suggest that advantages of LOT1 FCR over BR seen in clinical trials may not translate to community practice, whereas receiving novel LOT2 agents improved outcomes. This trial was registered at www.clinicaltrials.gov as NCT01081015.
Sympathetic neural recruitment strategies following acute intermittent hypoxia in humans
Ott, Elizabeth P., Jacob, Dain W. , Baker, Sarah E. , Holbein, Walter W., Scruggs, Zachariah M., Shoemaker, J. Kevin , Limberg, Jacqueline K. , Shoemaker, J Kevin , Baker, Sarah E

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | April 8, 2020 | Volume: 318 | Issue: 5 | Pages: R961-R971

10.1152/ajpregu.00004.2020 | PMID 32267729 Get It

We examined the effect of acute intermittent hypoxia (IH) on sympathetic neural firing patterns and the role of the carotid chemoreceptors. We hypothesized exposure to acute IH would increase muscle sympathetic nerve activity (MSNA) via an increase in action potential (AP) discharge rates and within-burst firing. We further hypothesized any change in discharge patterns would be attenuated during acute chemoreceptor deactivation (hyperoxia). MSNA (microneurography) was assessed in 17 healthy adults (11 male/6 female; 31 ± 1 yr) during normoxic rest before and after 30 min of experimental IH. Prior to and following IH, participants were exposed to 2 min of 100% oxygen (hyperoxia). AP patterns were studied from the filtered raw MSNA signal using wavelet-based methodology. Compared with baseline, multiunit MSNA burst incidence ( P < 0.01), AP incidence ( P = 0.01), and AP content per burst ( P = 0.01) were increased following IH. There was an increase in the probability of a particular AP cluster firing once ( P < 0.01) and more than once ( P = 0.03) per burst following IH. There was no effect of hyperoxia on multiunit MSNA at baseline or following IH ( P > 0.05); however, hyperoxia following IH attenuated the probability of particular AP clusters firing more than once per burst ( P < 0.01). Acute IH increases MSNA by increasing AP discharge rates and within-burst firing. A portion of the increase in within-burst firing following IH can be attributed to the carotid chemoreceptors. These data advance the mechanistic understanding of sympathetic activation following acute IH in humans.
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, William J. , Anderson, Benjamin O. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Blair, Sarah L. , Burstein, Harold J. , Dang, Chau T. , Goldstein, Lori J. , Isakoff, Steven J. , Lyons, Janice A., Matro, Jennifer M. , Moran, Meena S. , Patel, Sameer A. , Pierce, Lori J. , Sitapati, Amy M. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Burns, Jennifer L. , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Marcom, Paul Kelly , Mayer, Ingrid A. , Mortimer, Joanne , O'Regan, Ruth M , Rugo, Hope S. , Smith, Karen L. , Soliman, Hatem Hussein , Ward, John Headley , Young, Jessica S. , Kumar, Rashmi , Telli, Melinda L

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2020 | Volume: 18 | Issue: 4 | Pages: 452-478

10.6004/jnccn.2020.0016 | PMID 32259783 Get It

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Microanatomical considerations for safe uncinate removal during anterior cervical discectomy and fusion: 10‐year experience
Clifton, William , Valero‐Moreno, Fidel, Vlasak, Alexander , Damon, Aaron , Tubbs, R. Shane , Merrill, Sarah , Pichelmann, Mark A., Pichelmann, Mark, Clifton, William E

Mayo Clinic

Clinical Anatomy | April 2, 2020 | Volume: 33 | Issue: 6 | Pages: 920-926

10.1002/ca.23596 | PMID 32239547 Get It

AbstractCervical radiculopathy from uncovertebral joint (UVJ) hypertrophy and nerve root compression often occurs anterior and lateral within the cervical intervertebral foramen, presenting a challenge for complete decompression through anterior cervical approaches owing to the intimate association with the vertebral artery and associated venous plexus. Complete uncinatectomy during anterior cervical discectomy and fusion (ACDF) is a controversial topic, many surgeons relying on indirect nerve root decompression from restoration of disc space height. However, in cases of severe UVJ hypertrophy, indirect decompression does not adequately address the underlying pathophysiology of anterolateral foraminal stenosis. Previous reports in the literature have described techniques involving extensive dissection of the cervical transverse process and lateral uncinate process (UP) in order to identify the vertebral artery for safe removal of the UP. Recent anatomical investigations have detailed the microanatomical organization of the fibroligamentous complex surrounding the UP and neurovascular structures. The use of the natural planes formed from the encapsulation of these connective tissue layers provides a safe passage for lateral UP dissection during anterior cervical approaches. This can be performed from within the disc space during ACDF to avoid extensive lateral dissection. In this article, we present our 10‐year experience using an anatomy‐based microsurgical technique for safe and complete removal of the UP during ACDF for cervical radiculopathy caused by UVJ hypertrophy.
Author response: Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria
McGregor, Tracy L., Yee, Elaine, Nioi, Paul , Ticau, Simina , Pelosi, Marissa, Loken, Perry R , Lawlor, Deborah A, Huang, Qin , Erbe, David V., Hunt, Karen A. , Mason, Dan , Finer, Sarah , Lawlor, Deborah A, Fauman, Eric B. , Griffiths, Chris , MacArthur, Daniel G. , Trembath, Richard C. , Oglesbee, Devin , Lieske, John C. , Wright, John , Heel, David A. van

Mayo Clinic

No container title available | March 31, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.54363.sa2 Get It

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
Bhat, Shubha , Altajar, Sarah, Shankar, D. , Zahorian, Toni, Robert, Regine, Qazi, Taha , Shah, Bhavesh , Shah, Bhavesh, Farraye, Francis A.

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | March 30, 2020 | Volume: 26 | Issue: 4 | Pages: 410-416

10.18553/jmcp.2020.26.4.410 | PMID 32223602 Get It

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation
Jankú, Filip , Dowlati, Afshin , Forester, Martin, Blagden, Sarah P. , Schmitz, Debora, Adjei, Alex A. , Johnson, Faye M. , Opyrchal, Mateusz , Hierro, Cinta , Wicki, Andreas

Mayo Clinic

Molecular Cancer Therapeutics | March 26, 2020 | Volume: 18 | Issue: 12_Supplement | Pages: B109-B109

10.1158/1535-7163.targ-19-b109 Get It

Abstract Background: Bimiralisib is a balanced dual panPI3K/mTOR inhibitor, which demonstrated anti-cancer activity in a number of preclinical models. Pharmacokinetic (PK) data suggested that intermittent targeting of the PI3K/mTOR pathway could be preferable to continuous daily dosing. Preclinical models in squamous cell head and neck cancer (SCCHN) demonstrated that NOTCH1 Loss of Function (LoF) mutations were associated with efficacy of bimiralisib and other PI3K inhibitors. Methods: We conducted a first-in-human dose-escalation study (3+3 design) to identify the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose-limiting toxicities (DLT) and overall safety (CTCAE v4) of bimiralisib administered either as a continuous (80 mg – 120 mg daily) or one of two intermittent schedules (schedule A: twice weekly 80 mg – 200 mg on Day 1 and 2, or schedule B: twice weekly 80mg – 200 mg on Day 1 and 4) until disease progression or unacceptable adverse events (AEs). Eligible patients had histologically confirmed solid cancers refractory to standard therapies, ECOG &lt;1, life expectancy &gt;12 weeks, adequate bone marrow, liver, and renal functions, HgbA1c &lt;7%, and fasting plasma glucose &lt; 7.0mmol/L. Tumor responses were evaluated according to RECIST v1.1 every 6 weeks. PK and blood biomarkers were analyzed. Results: 70 patients (female, 70%; white, 93%; median age 57 years [range, 49-65]) with heavily pretreated advanced solid cancers were enrolled (continuous schedule, 21; intermittent schedule A, 25; intermittent schedule B, 24). The MTD for the continuous schedule was established as 80 mg daily. For all treatment groups, DLTs included grade 2 and 3 fatigue. Clinically significant treatment-related AEs included fatigue in the continuous schedule, none in the intermittent schedule A and diarrhea, hyperglycemia in the intermittent schedule B. Intermittent schedules A and B did not reach the MTD, and after review of PK data, 140 mg administered in schedule A was selected as the RP2D for further exploration. Day 1 peak plasma concentration proportionally increased with increasing doses of bimiralisib only up to 140mg. Weekly AUC on intermittent dosing at all dose levels studied were considerably lower than continuous daily dosing at 80mg. There was one partial response (PR, -85% per RECIST) in a heavily pretreated patient with SCCHN and NOTCH1 LoF mutation, which was maintained for 8.2 months until death from pulmonary artery rupture in the setting of known fistula (assessed as unrelated to bimiralisib). In addition, 30 (42.9%) pts achieved stable disease (SD) including one with anal SCC carrying a NOTCH1 LoF mutation. SD &gt; 6 months was observed in five pts (23.8%) in continuous schedule, 12 (48%) in intermittent schedule A, and 13 (54.2%) in intermittent schedule B. Results on patients, who consented to the serial circulating tumor DNA collection will be presented. Conclusions: Bimiralisib was well tolerated and RP2D of 140 mg given orally twice weekly on Days 1 and 2 was selected for further studies. In agreement with our preclinical models, there was an encouraging activity in a SCCHN patient with NOTCH1 LoF mutation and this observation is now being validated in a proof-of-concept phase 2 study (NCT03740100). Citation Format: Filip Janku, Faye M. Johnson, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro, Martin Forester, Sarah P. Blagden, Andreas Wicki, Debora Schmitz, Alex A. Adjei. Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B109. doi:10.1158/1535-7163.TARG-19-B109
Abstract PD7-06: A randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer
Kuffel, Mary J., Buhrow, Sarah A. , McGovern, Renee M., Black, John L. , Dockter, Travis , Liu, Minetta C. , Hawse, John R. , Doroshow, James H. , Storniolo, Anna Maria , Collins, Jerry M. , Streicher, Howard , Ames, Matthew M. , Goetz, Matthew P. , Suman, Vera J. , Reid, Joel M. , Symmans, W. Fraser , Ingle, James N. , Partridge, Ann H. , Carey, Lisa A.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: PD7-06-PD7-06

10.1158/1538-7445.sabcs19-pd7-06 Get It

Abstract Background: Endx is a Tam metabolite with promising antitumor activity in Tam and aromatase inhibitor (AI) resistant estrogen receptor (ER) positive (+) metastatic breast cancer (MBC). Methods: This randomized phase II study compared progression-free survival (PFS) and toxicity of Endx 80 mg/day to Tam 20 mg/day in patients (pts) with ER+ MBC. Eligibility included postmenopausal women, ECOG PS 0-2, prior progression on AI but not Tam (unlimited endocrine therapy [ET] lines allowed), and a preregistration biopsy confirming ER+ (&gt;10% nuclear staining) and HER2-negative MBC. Stratified randomization was used balancing prior CDK 4/6 inhibitor (CDK 4/6i) use and/or everolimus (yes/no), measurable disease (yes/no) and endocrine resistance (primary/secondary) between arms. Pts randomized to Tam were allowed to cross over to Endx at progression. Due to short expected median PFS, differences in PFS were assessed using approaches for interval-censored data (ICD). 40 eligible pts were to be randomized to each arm so a one-sided alpha=0.10 generalized log-rank test (GLRT) would have a 90% chance of detecting a 50% decrease in hazard of disease progression with Endx (median: 6 months) relative to Tam (median: 3 months). Secondary endpoints include clinical benefit rate (stable or partial response &gt; 6 cycles) (CBR) for measurable and non-measurable disease. Pharmacokinetic (PK) data were obtained Day (d) 1 (4 hour), end of cycle 2, and at time of progression. Results: From March 2015 to March 2017, 108 women with endocrine refractory recurrent or MBC were preregistered. 27 pts did not register due to: biopsy demonstrating ER-/HER2- (3 pts), ER+/HER2+ (5 pts), cancer other than breast (3 pts), no cancer in specimen (6 pts), brain metastases (2 pts), acute infection (1 pt), progression on or recent use of Tam (2 pts), or pt refusal (5 pts). 4/81 pts who registered were excluded due to ineligibility (3 pts) or refusal to start protocol treatment (1 pt). The study cohort consisted of 40 pts randomized to Endx and 37 pts to Tam. The median (m) number of ETs in the metastatic setting was 2 (range 1-4) for each arm including prior CDK 4/6i (Endx: 42.5%, Tam: 29.7%) and everolimus (Endx: 35.0%, Tam: 40.5%). The m cycle number was 6 for Endx (range: 1-35) and 3 for Tam (range: 1-42). PFS for Endx was not significantly different compared to Tam (HR= 0.77; 95% CI: 0.49-1.22, GLRT p=0.309; mPFS: Endx 130 days [95% CI: 76-138 days] and Tam 42 days [95%CI: 24-129 days]). However, PFS was significantly longer in pts with no prior CDK 4/6i in the Endx arm (GLRT p=0.002; HR(no/yes)=0.31; 95%CI: 0.15-0.65) but not in the Tam arm (GLRT p=0.708) (unplanned analysis). Severe (grade (G) 3+) toxicities included: Endx G3 hypertriglyceridemia (3 pts); Tam: G3 hypertension with G2 stroke (1 pt), G3 thromboembolic event (1 pt), and G3 abdominal, bone and liver pain (1 pt). In Endx arm, d1 m Endx plasma concentration (conc) was 216 ng/ml (n=17; range: 144-400). For Tam arm, d1 m Tam conc was 17 ng/ml (n=17; range:11-23) (Endx not detectable). For the 25 pts that crossed over to Endx, CBR was 28.0% (90% CI: 14.0-46.2%) and 14 pts had pk data at progression. A lower median Endx conc (6 ng/ml range: 3.3-16.3) was observed in Tam patients at progression who then had Endx clinical benefit compared to Tam pts without clinical benefit after Endx crossover (median Endx 12 ng/ml; range 4.4-36.6).Conclusions: In endocrine-resistant breast cancer, Z-Endx was not significantly superior to Tam, but clinical benefit was observed in 28% that crossed over to Endx after Tam progression. In pts with no prior CDK 4/6i, the observation of significantly longer PFS in the Endx arm is hypothesis generating. Support: U10CA180821, U10CA180882, U24CA196171, U10CA180820 (ECOG-ACRIN), https://acknowledgments.alliancefound.org; Clinical Trials.gov Identifier:NCT02311933 Citation Format: Matthew P. Goetz, Vera J Suman, Joel M Reid, Mary Kuffel, Sarah A Buhrow, Renee M McGovern, John Black, Travis Dockter, William F Symmans, Minetta C Liu, John R Hawse, James Doroshow, Anna M Storniolo, Jerry M Collins, Howard Streicher, Matthew M Ames, James N Ingle, Ann Partridge, Lisa Carey. A randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD7-06.